Insider Buying: AgomAb Therapeutics (NASDAQ:AGMB) Director Purchases 10,000 Shares of Company Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 21st. The shares were purchased at an average price of $8.88 per share, with a total value of $88,800.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at $222,000. This trade represents a 66.67% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

AgomAb Therapeutics Price Performance

NASDAQ AGMB traded down $0.07 during mid-day trading on Thursday, reaching $9.04. 10,126 shares of the stock were exchanged, compared to its average volume of 135,952. AgomAb Therapeutics NV has a one year low of $7.92 and a one year high of $17.82. The stock has a 50 day simple moving average of $11.70 and a 200-day simple moving average of $11.78.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, sell-side analysts forecast that AgomAb Therapeutics NV will post -1.77 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. B. Riley Financial began coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating for the company. HC Wainwright reissued a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday. Finally, Piper Sandler initiated coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They set an “overweight” rating and a $60.00 price target on the stock. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.